Longevity News

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

Source: PR Newswire • Published: 24 Aug 2026, 00:00

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

Comparative oncology collaboration examining a selective cancer therapy in naturally occurring animal tumors to guide which human indications and combinations to pursue.

Key Takeaways
  • Targeting Accelerated Human Clinical Indication Expansion USA - English India - English TAIPEI
  • Collaboration will be led by Lecturer Daiki Kato
  • Findings will directly inform indication selection and combination regimen design for future human trials
Read Original Source